CARDIOPROTECTIVE EFFECT OF TRIPLE THERAPY FOR HYPERTENSION


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Analysis of three-component therapy with amlodipine, indapamide, and renin-angiotensin system blockers allows it to be considered as optimal in reducing the risk of cardiovascular events in most hypertensive patients.

全文:

受限制的访问

作者简介

L. Khafizova

Republican Specialized Center of Cardiology

Candidate of Medical Sciences

G. Khamidullaeva

Republican Specialized Center of Cardiology

Email: gulnoz0566@mail.ru
MD

参考

  1. The MRFIT research group. Multiple Risk Factor Intervention Trial. Risk factor changes and mortality results // JAMA. - 1982; 248: 1465-77.
  2. Диагностика и лечение артериальной гипертензии. Рекомендации ВНОК (третий пересмотр) // Кардиоваск. тер. и профилакт. - 2008; 7 (Прил. 2): 31.
  3. Sesso H., Rosner M., Hennekens C. et al. Systolic and diastolic blood pressure, pulse pressure and mean arterial pressure as predictors of cardiovascular disease risk in men // Hypertension. - 2000; 36: 801-7.
  4. Шляхто Е.В., Кондри А.О. Структурно-функциональные изменения миокарда у больных гипертонической болезнью // Кардиология. - 1999; 6: 78-82.
  5. Хафизова Л.Ш., Хамидуллаева Г.А. Влияние трехмесячной комбинированной терапии индапамида с лерканидипином на параметры внутрисердечной гемодинамики // Центрально-Азиатский медицинский журнал. - 2014; том 20 (4): 271-5.
  6. Aznaouridis K., Stamatelopoulos K.S, Karatzis E. et al. Acute effects of renin-angiotensin system blockade on arterial function in hypertensive patients // J. Hum. Hypertens. - 2007; 21: 654-63.
  7. Hansson L., Zanchetti A. The Hypertension Optimal Treatment study (The HOT Study) - patient characteristics: randomization, risk profiles, and early blood pressure results // Blood Press. - 1994; 3: 322-7.
  8. Грачев А.В. Центральные и периферические механизмы адаптации сердечно-сосудистой системы у больных артериальной гипертонией (патогенетические и терапевтические аспекты). Дис.. д-ра мед. наук. Ташкент, 2001; 364 с.
  9. The Task Force for the Management of Arterial Hypertension of the ESH and ESC // J. Hypertens. - 2013; 31 (7): 1281-357.
  10. Savage D., Garrison R., Kannel W. et al. The spectrum of left ventricular hypertrophy in a general population sample: The Framingham Study // Circulation. -1987; 75: 26.
  11. Borgi C., Morbini M., Cicero A. Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine // J. Cardiovasc. Med. - 2015; 16.
  12. Kalman Toth on behalf of PIANIST investigators. Antihypertensive efficacy of triple combination perindopril/indapamide plus amlodipine in high-risk hypertensives: results of the PIANIST Study // Am. J. Cardiovasc. Drugs. - 2014; 14: 137-45.
  13. Jamerson K., Weber M., Bakris G. et al. Benazepril plus amlodipine or hydrochlortiazide for hypertension in high risk patients // N. Engl. J. Med. - 2008; 359: 2417-28.
  14. Fagard R., Cells H., Thijs L. et al. Regression of left ventricular mass by antihypertensive treatment: a meta-analysis of randomized comparative studies // Hypertension. - 2009; 54: 1084-91.
  15. Devereux R., Wachtell K., Gerdts E. et al. Prognostic significance of left ventricular mass change during treatment of hypertension // JAMA. - 2004; 292: 2350-6.
  16. Dahlof B., Devereux R., Julius S. et al. Characteristics of 9194 patients with left ventricular hypertrophy. The LIFE Study // Hypertension. - 1998; 32: 989-97.

补充文件

附件文件
动作
1. JATS XML

版权所有 © Russkiy Vrach Publishing House, 2017